MX2021001938A - Inmunoterapia dirigida a antigenos kras o her2. - Google Patents
Inmunoterapia dirigida a antigenos kras o her2.Info
- Publication number
- MX2021001938A MX2021001938A MX2021001938A MX2021001938A MX2021001938A MX 2021001938 A MX2021001938 A MX 2021001938A MX 2021001938 A MX2021001938 A MX 2021001938A MX 2021001938 A MX2021001938 A MX 2021001938A MX 2021001938 A MX2021001938 A MX 2021001938A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- her2
- kras
- recombinant
- neoantigen
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108091008324 binding proteins Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 102200006531 rs121913529 Human genes 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 201000009036 biliary tract cancer Diseases 0.000 abstract 1
- 208000020790 biliary tract neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En la presente se proporcionan proteínas de unión y receptores de células T recombinantes de alta afinidad (TCR) específicos para los neoantígenos KRAS G12V o Her2-ITD. También se proporcionan composiciones y células hospedadoras recombinantes que codifican para y/o expresan las proteínas de unión y/o TCR recombinantes de alta afinidad. Las composiciones y células hospedadoras recombinantes se pueden usar para tratar a un sujeto que tiene cáncer de pulmón de células no pequeñas (NSCLC), cáncer colorrectal, cáncer de páncreas, cáncer de ovario, cáncer de mama, cáncer de tracto biliar, una indicación en donde un neoantígeno KRAS G12V es una diana terapéutica, o una indicación en donde un neoantígeno Her2-ITD es una diana terapéutica. También se proporcionan vacunas relacionadas, terapias de vacunas y regímenes de vacunación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862721439P | 2018-08-22 | 2018-08-22 | |
PCT/US2019/047550 WO2020041501A1 (en) | 2018-08-22 | 2019-08-21 | Immunotherapy targeting kras or her2 antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021001938A true MX2021001938A (es) | 2021-04-19 |
Family
ID=68000056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021001938A MX2021001938A (es) | 2018-08-22 | 2019-08-21 | Inmunoterapia dirigida a antigenos kras o her2. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210340201A1 (es) |
EP (1) | EP3841113A1 (es) |
JP (1) | JP2021534752A (es) |
KR (1) | KR20210049119A (es) |
CN (1) | CN112912387A (es) |
AU (1) | AU2019324162A1 (es) |
BR (1) | BR112021003031A8 (es) |
CA (1) | CA3109496A1 (es) |
IL (1) | IL280804A (es) |
MX (1) | MX2021001938A (es) |
WO (1) | WO2020041501A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112300269B (zh) * | 2020-09-29 | 2022-12-09 | 中国科学院微生物研究所 | Kras突变特异性t细胞受体筛选及抗肿瘤用途 |
US20240100162A1 (en) * | 2020-12-22 | 2024-03-28 | Amgen Inc. | Mage-b2-specific t-cell receptors |
CN113755495B (zh) * | 2021-09-22 | 2022-09-06 | 陈天睿 | 基因编辑技术在治疗癌症中的应用 |
WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
CN101284873A (zh) * | 1999-06-30 | 2008-10-15 | 科里克萨有限公司 | 用于肺癌治疗和诊断的组合物和方法 |
ES2292994T3 (es) | 2002-03-15 | 2008-03-16 | Cellectis | Meganucleasas hibridas y de cadena sencilla y su utilizacion. |
JP4966006B2 (ja) | 2003-01-28 | 2012-07-04 | セレクティス | カスタムメイドメガヌクレアーゼおよびその使用 |
EP1850860A2 (en) | 2005-01-13 | 2007-11-07 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
EP1945762B1 (en) | 2005-10-18 | 2013-05-01 | Precision Biosciences | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
MX361299B (es) * | 2010-10-05 | 2018-11-30 | Otsuka Pharmaceutical Co Ltd Star | Metodo para activar celulas auxiliares. |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
GB2537000C (en) | 2012-05-25 | 2019-10-09 | Univ California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
DK2921557T3 (en) | 2012-12-12 | 2016-11-07 | Broad Inst Inc | Design of systems, methods and optimized sequence manipulation guide compositions |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
SG11201504764SA (en) | 2012-12-19 | 2015-07-30 | Amplimmune Inc | Anti-human b7-h4 antibodies and their uses |
GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
AU2014350051A1 (en) | 2013-11-18 | 2016-07-07 | Crispr Therapeutics Ag | CRISPR-Cas system materials and methods |
US9775892B2 (en) * | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
CN106804108B (zh) | 2014-09-12 | 2021-08-10 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
WO2016054638A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
HUE061084T2 (hu) | 2015-02-19 | 2023-05-28 | Compugen Ltd | PVRIG elleni antitestek és alkalmazási eljárások |
BR112017025728A2 (pt) * | 2015-06-16 | 2018-08-07 | Targovax Asa | fragmentos mutantes da proteína ras |
JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
KR20220163523A (ko) * | 2016-03-31 | 2022-12-09 | 바이오엔테크 유에스 인크. | 신생항원 및 이것의 사용 방법 |
US11723962B2 (en) | 2016-05-04 | 2023-08-15 | Fred Hutchinson Cancer Center | Cell-based neoantigen vaccines and uses thereof |
WO2017193104A1 (en) * | 2016-05-06 | 2017-11-09 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for mart-1 |
-
2019
- 2019-08-21 CA CA3109496A patent/CA3109496A1/en active Pending
- 2019-08-21 WO PCT/US2019/047550 patent/WO2020041501A1/en active Application Filing
- 2019-08-21 US US17/270,400 patent/US20210340201A1/en active Pending
- 2019-08-21 CN CN201980070018.XA patent/CN112912387A/zh active Pending
- 2019-08-21 BR BR112021003031A patent/BR112021003031A8/pt unknown
- 2019-08-21 KR KR1020217007912A patent/KR20210049119A/ko active Search and Examination
- 2019-08-21 EP EP19773210.0A patent/EP3841113A1/en active Pending
- 2019-08-21 MX MX2021001938A patent/MX2021001938A/es unknown
- 2019-08-21 JP JP2021509790A patent/JP2021534752A/ja active Pending
- 2019-08-21 AU AU2019324162A patent/AU2019324162A1/en active Pending
-
2021
- 2021-02-11 IL IL280804A patent/IL280804A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021003031A8 (pt) | 2023-05-02 |
AU2019324162A1 (en) | 2021-03-04 |
WO2020041501A1 (en) | 2020-02-27 |
JP2021534752A (ja) | 2021-12-16 |
BR112021003031A2 (pt) | 2021-05-11 |
US20210340201A1 (en) | 2021-11-04 |
IL280804A (en) | 2021-04-29 |
EP3841113A1 (en) | 2021-06-30 |
CN112912387A (zh) | 2021-06-04 |
CA3109496A1 (en) | 2020-02-27 |
KR20210049119A (ko) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021001938A (es) | Inmunoterapia dirigida a antigenos kras o her2. | |
MX2022000012A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
MX2022005060A (es) | Novedosos peptidos y combinaciones de peptidos para usarse en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon no microcitico (nsclc) y otros canceres. | |
AU2018250464B2 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
PH12018501865A1 (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
MX2022000219A (es) | Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres. | |
MX2018004140A (es) | Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer pulmonar microcelular y otros tipos de cancer. | |
MX2017014008A (es) | Nuevos peptidos y nuevas combinaciones de peptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cancer. | |
EP3545965A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
MX2020012772A (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer. | |
AU2019343184A8 (en) | Compositions and methods for treating cancer with anti-CD123 immunotherapy | |
MX2022007902A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
CY1122436T1 (el) | Αντισωματα εναντι του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egfr) | |
PH12020500051A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers | |
PH12017501994A1 (en) | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers | |
MY198087A (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | |
MX351642B (es) | Vacuna para virus de leucemia felina recombinante que contiene gen de envoltura del virus de leucemia felina optimizado. | |
MX2021005308A (es) | Receptores de celulas t especificos para mesotelina y su uso en inmunoterapia. | |
EA202091879A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
MY197679A (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers | |
MY197301A (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers | |
MY197511A (en) | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers |